These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Strontium-89 for bone metastases from prostate cancer: an update]. Zhao WW; Xie P; Deng HF Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560 [TBL] [Abstract][Full Text] [Related]
24. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy. Malmberg I; Persson U; Ask A; Tennvall J; Abrahamsson PA Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886 [TBL] [Abstract][Full Text] [Related]
25. [2 years of experience with 89Sr therapy of multiple bone metastases (author's transl)]. Correns HJ; Mitterlechner E; Buchali K; Schnorr D; Seidel C; Mebel M Radiobiol Radiother (Berl); 1979 Jun; 20(3):360-2. PubMed ID: 515396 [No Abstract] [Full Text] [Related]
26. [Internal strontium-89 radiotherapy for malignant bony metastasis]. Lou C; Zhang D; Yu L Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):507-9. PubMed ID: 11859724 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of radioactive phosphorus in the palliation of metastatic bone lesions from carcinoma of the breast and prostate. Cheung A; Driedger AA Radiology; 1980 Jan; 134(1):209-12. PubMed ID: 6153129 [TBL] [Abstract][Full Text] [Related]
28. Clinical experience with strontium-89 in prostatic and breast cancer patients. Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027 [TBL] [Abstract][Full Text] [Related]
29. The palliation of osseous metastasis with 32P or 89Sr compared with external beam and hemibody irradiation: a historical perspective. Montebello JF; Hartson-Eaton M Cancer Invest; 1989; 7(2):139-60. PubMed ID: 2477119 [TBL] [Abstract][Full Text] [Related]
30. 89Strontium in the management of painful sceletal metastases. Kälkner KM; Westlin JE; Strang P Anticancer Res; 2000; 20(2B):1109-14. PubMed ID: 10810404 [TBL] [Abstract][Full Text] [Related]
31. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Baczyk M; Czepczyński R; Milecki P; Pisarek M; Oleksa R; Sowiński J Nucl Med Commun; 2007 Apr; 28(4):245-50. PubMed ID: 17325585 [TBL] [Abstract][Full Text] [Related]
33. Bone pain palliation with strontium-89 in cancer patients with bone metastases. Giammarile F; Mognetti T; Resche I Q J Nucl Med; 2001 Mar; 45(1):78-83. PubMed ID: 11456379 [TBL] [Abstract][Full Text] [Related]
34. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer]. Ma YB; Yan WL; Dai JC; Xu F; Yuan Q; Shi HH Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467 [TBL] [Abstract][Full Text] [Related]
35. Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following strontium-89 therapy. Leong C; McKenzie MR; Coupland DB; Gascoyne RD J Nucl Med; 1994 Oct; 35(10):1662-4. PubMed ID: 7931669 [TBL] [Abstract][Full Text] [Related]
36. Radionuclide-targeted therapy for the management of metastatic bone pain. Ackery D; Yardley J Semin Oncol; 1993 Jun; 20(3 Suppl 2):27-31. PubMed ID: 7684862 [TBL] [Abstract][Full Text] [Related]
37. Strontium-89 therapy for painful osseous metastatic prostate and breast cancer. Hansen DV; Holmes ER; Catton G; Thorne DA; Chadwick DH; Schmutz DA Am Fam Physician; 1993 Jun; 47(8):1795-800. PubMed ID: 7684554 [TBL] [Abstract][Full Text] [Related]